Laboratory of Molecular Pharmacology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, 920-1192, Japan.
Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, 606-8501, Japan.
Psychopharmacology (Berl). 2019 Jul;236(7):2235-2242. doi: 10.1007/s00213-019-05222-2. Epub 2019 Mar 13.
N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-L-valine methyl ester (5F-AMB) is a synthetic cannabinoid that has been distributed recently. Although inhalation of 5F-AMB produces adverse effects, such as impaired memory and disturbed consciousness, in humans, the psychopharmacological effects of 5F-AMB in rodents have not been investigated.
We first examined the effects of intraperitoneal and intracerebroventricular injections of 5F-AMB on anxiety-like behavior and locomotor activity in the open field (OF) test and recognition memory in the novel object recognition test (NOR) in C57BL/6J mice. We also examined whether a cannabinoid 1 (CB1) receptor antagonist AM251 blocks the effects of 5F-AMB. We next examined the effects of 5F-AMB infusion into the medial prefrontal cortex (mPFC), a brain region associated with anxiety and memory, on these tests.
Intraperitoneal injection of 5F-AMB (0.3 mg/kg) dramatically decreased locomotor activity in the OF, and this effect was partially reversed by AM251 (3 mg/kg). Intracerebroventricular infusion of 5F-AMB (10 nmol) produced an anxiolytic effect in the OF and impaired acquisition, but not retrieval, of recognition memory in the NOR, and these effects were blocked by co-infusion of AM251 (1.8 nmol). Bilateral intra-mPFC infusion of 5F-AMB (10 pmol/side) similarly produced impaired recognition memory acquisition, but no anxiolytic effect.
The results demonstrate that centrally administered 5F-AMB produces anxiolytic effect and impaired recognition memory acquisition via activation of CB1 receptors, while systemic 5F-AMB severely impaired locomotor activity. The mPFC is involved in 5F-AMB-induced impairment of recognition memory acquisition. However, other brain region(s) may contribute to the 5F-AMB-induced anxiolytic effect.
N-[[1-(5-氟戊基)-1H-吲唑-3-基]羰基]-L-缬氨酸甲酯(5F-AMB)是一种最近被分发的合成大麻素。虽然吸入 5F-AMB 会对人类产生不良影响,如记忆受损和意识障碍,但在啮齿动物中,5F-AMB 的精神药理学效应尚未得到研究。
我们首先研究了腹腔内和侧脑室注射 5F-AMB 对 C57BL/6J 小鼠旷场(OF)试验中焦虑样行为和运动活性以及新物体识别试验(NOR)中识别记忆的影响。我们还研究了大麻素 1(CB1)受体拮抗剂 AM251 是否阻断 5F-AMB 的作用。我们接下来研究了将 5F-AMB 输注到与焦虑和记忆相关的内侧前额叶皮质(mPFC)对这些测试的影响。
腹腔内注射 5F-AMB(0.3mg/kg)显著降低 OF 中的运动活性,而 AM251(3mg/kg)部分逆转了这种作用。侧脑室注射 5F-AMB(10nmol)在 OF 中产生抗焦虑作用,并损害 NOR 中识别记忆的获得,但不损害检索,而这些作用被 AM251(1.8nmol)共输注所阻断。双侧 mPFC 内注射 5F-AMB(10pmol/侧)同样导致识别记忆获得受损,但没有抗焦虑作用。
结果表明,中枢给予 5F-AMB 通过激活 CB1 受体产生抗焦虑作用和损害识别记忆获得,而全身给予 5F-AMB 则严重损害运动活性。mPFC 参与 5F-AMB 诱导的识别记忆获得障碍。然而,其他脑区可能有助于 5F-AMB 诱导的抗焦虑作用。